Poster above created for PNARS by Crystal Mathews
Animal are not predictive models for human drug or disease response — 95% of drugs that pass animal tests fail or cause harm in human trials.
IMBRUVICA (ibrutinib) – Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure – 2022-08-29
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion – 2022-02-03
PAXLOVID (nirmatrelvir and ritonavir) – Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions – 2022-01-17
Health Canada has initiated a safety review on Xeljanz and Xeljanz XR (tofacitinib), used to treat arthritis and ulcerative colitis, From Government of Canada, Recalls and Safety Alerts, April 6, 2021